H. Burmeister

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2

A. Addeo, M. Joerger, S. Rothschild, 2020, Cancer Immunology, Immunotherapy.

Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting

M. Fey, S. Aebi, O. Gautschi, 2010, Supportive Care in Cancer.

Reply to: Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score

H. Burmeister, 2012, Supportive Care in Cancer.

Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (RE

R. Winterhalder, A. Mueller, H. Hawle, 2019, Journal of Clinical Oncology.